DIAMEDICA THERAPEUTICS INC (DMAC) Stock Analyst Ratings
NASDAQ:DMAC - Nasdaq - CA25253X2077 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to DMAC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.16. This target is 25.35% above the current price.
DMAC was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about DMAC.
In the previous month the buy percentage consensus was at a similar level.
DMAC was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |